Effects of Exemestane and Tamoxifen treatment on bone texture analysis assessed by TBS in comparison with bone mineral density assessed by DXA in women with breast cancer.
Kalder, Matthias; Hans, Didier; Kyvernitakis, Ioannis; Lamy, Olivier; Bauer, Martina; Hadji, Peyman.
J Clin Densitom
; 17(1): 66-71, 2014 Jan-Mar.
Artigo em Inglês | MEDLINE | ID: mdl-23562130
Differential oestrogen receptor binding is associated with clinical outcome in breast cancer.
Bone mineral density following surgical oophorectomy and tamoxifen adjuvant therapy for breast cancer.
Mammographic density changes following discontinuation of tamoxifen in premenopausal women with oestrogen receptor-positive breast cancer.
Negative Impact of Aromatase Inhibitors on Proximal Femoral Bone Mass and Geometry in Postmenopausal Women with Breast Cancer.
Predictive factors for the efficacy of denosumab in postmenopausal Japanese women with non-metastatic breast cancer receiving adjuvant aromatase inhibitors: a combined analysis of two prospective clinical trials.
Mammographic Density Reduction as a Prognostic Marker for Postmenopausal Breast Cancer: Results Using a Joint Longitudinal-Survival Modeling Approach.
Long-term effect of aromatase inhibitors on bone microarchitecture and macroarchitecture in non-osteoporotic postmenopausal women with breast cancer.
Tamoxifen resistance and epigenetic modifications in breast cancer cell lines.
Elastosonographic evaluation of endometrium in women using tamoxifen for breast cancer.
Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study.